Since the B16F10 model is immunologically cold and unresponsive to most single-agent immunotherapies, we combined our immunocytokine treatment with TA99, a murine IgG2a tumor-targeting antibody against tumor-associated antigen tyrosinase-related protein-1. Here, TYRP1 is linked to neoplasm.